

Ah Receptor Mediated Suppression of Liver Regeneration through NC-XRE-Driven p21^{Cip1} Expression

Daniel P. Jackson, Hui Li, Kristen A. Mitchell, Aditya D. Joshi, and Cornelis J. Elferink

Department of Pharmacology and Toxicology, University of Texas Medical Branch,
Galveston, TX 77555-0654 (D.P.J., A.D.J., C.J.E.); Department of Pediatrics, University
of Texas Medical Branch, Galveston, TX 77555-0654 (H.L.); Department of Biological
Sciences, Boise State University, Boise, ID, 83725-1515 (K.A.M.)

Functional consequences of AhR mediated p21^{Cip1} expression

Corresponding Author: Cornelis Elferink
301 University Boulevard Route 0654
Galveston TX 77555-0654
Phone: (409) 772-9624
Fax: (409) 747-7050
Email: coelferi@utmb.edu

Number of Pages: 45
Number of Tables: 1
Number of Figures: 8
Number of References: 44
Abstract word count: 211
Introduction word count: 762
Discussion word count: 1,350

Abbreviations

AhR, aryl hydrocarbon receptor; BrdU, 5-bromo-2'-deoxyuridine; CDK, cyclin dependent kinase; ChIP, Chromatin Immunoprecipitation; CT, threshold cycle; IP, immunoprecipitate; NC-XRE, non-consensus XRE; PCR, polymerase chain reaction; PH, partial hepatectomy; qRT-PCR, quantitative real-time PCR; Rb, retinoblastoma tumor suppressor protein; RT, room temperature; TCDD, dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin; UTMB, University of Texas Medical Branch; WT, wild-type; XRE, xenobiotic response element;

Abstract

Previous studies in hepatocyte-derived cell lines and the whole liver, established that the aryl hydrocarbon receptor (AhR) can disrupt G₁ phase cell cycle progression following exposure to persistent AhR agonists such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Growth arrest was attributed to inhibition of G₁ phase cyclin-dependent kinase 2 (CDK2) activity. The present study examined the effect of TCDD exposure on liver regeneration following 70% partial hepatectomy in mice lacking the Cip/Kip inhibitors p21^{Cip1} or p27^{Kip1} responsible for regulating CDK2 activity. Assessment of the regenerative process in wild-type, p21^{Cip1} knock out, and p27^{Kip1} knock out mice confirmed that TCDD-induced inhibition of liver regeneration is entirely dependent on p21^{Cip1} expression. Compared to wild-type mice, the absence of p21^{Cip1} expression completely abrogated the TCDD inhibition, and accelerated hepatocyte progression through G₁ phase during the regenerative process. Analysis of the transcriptional response determined that increased p21^{Cip1} expression during liver regeneration involved an AhR dependent mechanism. Chromatin immunoprecipitation studies revealed that p21^{Cip1} induction required AhR binding to the newly characterized non-consensus xenobiotic response element, in conjunction with the tumor suppressor protein Kruppel-like Factor 6 functioning as an AhR binding partner. The evidence also suggests that AhR functionality following partial hepatectomy is dependent on a p21^{Cip1}-regulated signaling process, intimately linking AhR biology to the G₁ phase cell cycle program.

Introduction

The liver is the only solid organ known to be capable of regenerating organ mass in response to damage (Huang and Elferink, 2005). This is important given the role of the liver in metabolism of both endogenous and exogenous compounds. One such example is the metabolism of exogenous aromatic hydrocarbon compounds by enzymes of the cytochrome p450 system (Denison and Nagy, 2003). Central to both the regenerative and metabolic functions of the liver is the ligand-activated basic helix-loop-helix transcription factor of the Per-Arnt-Sim (PAS) family, known as the Aryl Hydrocarbon Receptor (AhR) (Fukunaga et al., 1995). The AhR is activated by numerous polycyclic and halogenated aromatic hydrocarbons, including the prototypical ligand 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) (Denison and Nagy, 2003). In humans TCDD is known to cause a number of deleterious health effects, including liver toxicity, immunotoxicity, dermal toxicity, tumor promotion, and developmental abnormalities (Safe, 1986). These effects of TCDD are all mediated by the AhR (Poland and Knutson, 1982; Nebert et al., 1993; Fernandez-Salguero et al., 1996).

In the absence of a ligand, the AhR exists in the cytosol bound by chaperones, including heat-shock proteins (Hankinson, 1995) and an immunophilin-like protein (Whitlock, 1999). Upon ligand binding, the AhR translocates to the nucleus, dissociates from the chaperones, and interacts with DNA-binding partners to regulate target gene expression. Canonically, the nuclear AhR heterodimerizes with the Aryl hydrocarbon receptor nuclear translocator (Arnt) (Probst et al., 1993; Reisz-Porszasz et al., 1994) and binds to a core recognition motif (5'-GCGTG-3') termed the Xenobiotic Response

Element (XRE) (Watson and Hankinson, 1992; Swanson et al., 1995). CYP1A1 represents the prototypical XRE-regulated AhR target gene (for review, see Denison et al., 2011). Recent studies however, have revealed that the TCDD activated AhR also forms a transcriptionally active heterodimeric complex with the Kruppel-like factor 6 (KLF6) protein bound to a non-consensus XRE (NC-XRE) (Huang and Elferink, 2012; Wilson et al., 2013)

It is now well accepted that the AhR plays an important role in cell cycle progression (Ma and Whitlock, 1996; Kolluri et al., 1999; Abdelrahim et al., 2003; Denison et al., 2011). Indeed, studies have shown that TCDD exposure leads to G₁ cell-cycle arrest in cell lines that express a functional AhR, but not in cell lines lacking AhR expression (Gottlicher and Wiebel, 1991),(Weiss et al., 1996). Previous work has also shown that the cell cycle effects depend on a direct interaction between the AhR and the active (hypophosphorylated) form of the retinoblastoma tumor suppressor protein (Rb) (Ge and Elferink, 1998; Elferink et al., 2001; Puga et al., 2000; Marlowe et al., 2004). One way the AhR-Rb interaction regulates cell-cycle progression is by repressing E2F-dependent gene expression thus preventing entry into S-phase (Marlowe et al., 2004; Puga et al., 2000). Separate from its role as a repressor complex, the AhR-Rb interaction also promotes gene expression consistent with Rb functioning as a transcriptional co-activator, where sustained receptor activity in 5L rat hepatoma cells leads to induction of the G₁-phase cyclin-dependent kinase inhibitor p27^{Kip1} (Kolluri et al., 1999; Levine-Fridman et al., 2004; Huang and Elferink, 2005). p27^{Kip1}, as well as p21^{Cip1} and the less well studied p57^{Kip2}, are members of the Cip/Kip family of cyclin-

dependent kinase inhibitors targeting CDK2 activity (Sherr and Roberts, 1995). We have previously shown that AhR activation by TCDD suppresses cell proliferation during partial hepatectomy-induced liver regeneration (Mitchell et al., 2006). The *in vivo* studies showed that CDK2 activity was diminished in the regenerating liver in mice pretreated with TCDD. It is noteworthy that the decrease in CDK2 activity was associated with increased binding of the p21^{Cip1} and p27^{Kip1} inhibitors to the CDK2-cyclin E complex. The receptor's role in hepatic cell cycle control is more complicated however. Abdelrahim and coworkers (Abdelrahim et al., 2003) showed that the AhR can both inhibit (MCF7 cells) and promote (HepG2 cells) cell growth, which was underscored by significant changes in the expression of several G₁-phase regulatory proteins in HepG2 cells. Likewise, while TCDD suppresses liver growth in hepatectomized mice, it promotes cell proliferation in animals treated with a hepatomitogen (Mitchell et al., 2010), despite suppression of CDK2 activity.

Given the role for p21^{Cip1} and p27^{Kip1} in G₁-phase cell cycle control, we set out to determine if these proteins are functionally required for the TCDD-induced inhibition of liver regeneration in hepatectomized animals. The present study examined the regenerative response following 70% partial hepatectomy in mice lacking either p21^{Cip1} or p27^{Kip1}. The data reveal that p21^{Cip1}, rather than p27^{Kip1}, is essential for the TCDD-induced growth arrest, and that p21^{Cip1} induction by TCDD involves the recently described novel AhR-KLF6 complex binding to a NC-XRE in the p21^{Cip1} promoter.

Materials and Methods

Animals. C57Bl/6 (WT), p21^{Cip1} KO, and p27^{Kip1} KO mice were purchased from Jackson Laboratories. These animals were maintained on a 12 hour light/dark cycle, in a temperature controlled facility in the UTMB animal resource center, with food and water *ad libitum*. Female mice 8-10 weeks old were used for our experiments. Animals were euthanized via isoflurane overdose followed by cervical dislocation. All experiments were conducted in accordance with approved IACUC procedures.

Chemicals. As reported previously (Mitchell et al., 2010), TCDD was purchased from Cerilliant (Round Rock, TX) and dissolved in anisole, followed by dilution in peanut oil to 2 mg/ml. TCDD was administered via oral gavage at 20 µg TCDD/kg body weight. Control animals received similar amounts of anisole dissolved in peanut oil.

Partial Hepatectomy. Partial hepatectomy (PH) or sham surgery was performed as previously described (Mitchell et al., 2006). Briefly, mice were anesthetized via isoflurane inhalation and PH performed, resecting ~70% of the liver (as previously described by Higgins and Anderson, 1931). Sham surgery involved anesthetization followed by opening the abdominal cavity and gentle manipulation of the liver tissue without resection. Mice were allowed to recover and were then euthanized at indicated times by isoflurane inhalation followed by cervical dislocation. All animal handling and surgical procedures were performed in strict compliance with an approved UTMB IACUC protocol.

BrdU Incorporation. In order to measure cell proliferation following partial hepatectomy, we performed 5-bromo-2'-deoxyuridine (BrdU) incorporation studies as previously described (Mitchell et al., 2006). Briefly, 50 mg/kg BrdU (Sigma-Aldrich, St. Louis, MO) was administered i.p. 2 hours before euthanization. Tissues were then resected and fixed in 10% buffered formalin for 18 hours. For continuous labeling studies mice were provided with drinking water containing 0.8 mg/ml BrdU (bottles shielded from UV light) immediately following surgery until mice were sacrificed, at which time tissue was removed and fixed in 10% buffered formalin for 18 hours. Fixed tissues were sectioned, processed, and stained by the UTMB Histopathology Core Facility. Briefly, sections were stained for BrdU incorporation using a biotinylated anti-BrdU antibody (Invitrogen, Carlsbad, CA). These sections were then incubated with avidin-conjugated HRP and 3,3'-diaminobenzidine. For the analysis of proliferation, the numbers of brown stained (BrdU positive) nuclei were counted in six randomly selected low power fields per animal and expressed as a percentage of the total number of nuclei.

Immunoprecipitation/Western Blotting. Western Blots were conducted as previously described (Mitchell et al., 2006). Briefly, fresh frozen liver tissue was homogenized using a polytron in TGH buffer (50 mM HEPES pH7.4, 150 mM NaCl, 1.5 mM MgCl₂, 1mM EGTA pH 8.0, 1%Triton X-100, 10% Glycerol) supplemented with 1 mM PMSF, 10 mM NaF, 1 mM Na₃VO₄, and 5 µg/ml protease inhibitors (Sigma p8340). Protein concentrations were determined using the DC protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA). For immunoprecipitation experiments, 50 µg of total protein from

whole cell lysates was incubated with 2 μ g anti-CDK2 antibody (sc-163 or sc-163g; Santa Cruz Biotechnology) for 4 hours at 4°C. Protein A or Protein G beads were then added and incubated 1 hour at 4°C. Beads were washed 5 times in NETN buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.5% Nonidet P-40, 1 mM EDTA) and resuspended in 2x SDS loading buffer then boiled for 10 minutes at 100°C and fractionated on SDS gel as detailed below.

For western blots, proteins were resolved on SDS-polyacrylamide (10%) gel and transferred to PVDF membranes (Amersham Hybond-LFP, GE Healthcare Life Sciences). Membranes were blocked for 1 hour at RT in 5% dry milk in Tris-buffered saline, 0.1% Tween 20 (v/v) (TBST), and incubated overnight at 4°C with primary antibody in 5% milk in TBST. Membranes were washed 3x with TBST, 10 minutes each, and incubated at RT for 1 hour with secondary antibody in 5% milk in TBST. Finally, membranes were washed 1x with TBST for 15 minutes and visualized on the Typhoon Trio Variable Mode Imager (GE Healthcare Life Sciences). Primary antibodies used include CDK2 (sc-163), p21^{Cip1} (sc-6246), p27^{Kip1} (sc-776), cyclin A (sc-751), and cyclin E (sc-247) (Santa Cruz Biotechnology). Secondary antibodies were Cy3/Cy5 anti-mouse or anti-rabbit (GE Healthcare Life Sciences). Blot analysis and densitometry were performed using ImageQuant software (GE Healthcare Life Sciences).

Kinase Assay. Kinase assays were conducted as previously described (Mitchell et al., 2006). Briefly, 500 μ g total protein was subjected to CDK2 immunoprecipitation as described above, except washed for 4 times in NETN (rather than 5), 1x in kinase assay

buffer (see (Mitchell et al., 2006)), resuspended in 15µl kinase assay buffer supplemented with 10µg of histone H1 and 5µCi (³²P)-ATP (3000 Ci/mmol) and incubated for 40 minutes at RT. The reaction was stopped with 15 µl of 2x SDS loading buffer and reaction products were resolved on 15% SDS-polyacrylamide gel and analyzed by autoradiography.

RT-PCR. RNA was isolated from total liver tissue using TRIzol (Life Technologies corp.) according to the manufacturers recommendations. SuperScript II (Invitrogen) was used for first strand cDNA synthesis using 1 µg total RNA according to the manufacturers recommendations. 2 µl of this cDNA was used as template for the PCR reactions. 10X PCR buffer (Fischer) was diluted to 1x with dH₂O, forward and reverse primers (table 1) were added at 0.2 µM final concentration, and 10 U/per reaction of *Taq* DNA polymerase was added to make a master mix. cDNA was warmed to 95°C before adding the master mix (hot-start). Cycling parameters were 95°C for 45 seconds, 68°C for 30 seconds, and 72°C for 90 seconds. This sequence was used to amplify the target sequence for the indicated number of cycles and a final extension at 72°C for 6 minutes was used. Reaction products were resolved on a 0.8% agarose EtBr gel. Gels were visualized on a Typhoon Trio variable mode imager (GE Healthcare Life Sciences) and densitometry was analyzed with ImageQuant software (GE Healthcare Life Sciences).

Quantitative Real-Time RT-PCR. Total RNA was isolated from fresh liver tissue using TRIzol (Life Technologies) according to the manufacturer's recommendations.

Quantitative real-time PCR (qRT-PCR) was performed by the Real-Time PCR core facility at the University of Texas Medical Branch as previously described (Mitchell et al., 2006). Briefly, RT-PCR was performed using 20ng of total RNA for target gene detection. Target gene expression (2-CT) was calculated, following normalization of the triplicate CT value to 18S rRNA.

Chromatin Immunoprecipitation (ChIP). ChIP experiments were performed as previously described (Huang and Elferink, 2012; Wilson et al., 2013). Briefly, C57Bl/6 mice were treated *in vivo* with 20 µg TCDD per kg body weight, or an equivalent amount of vehicle via oral gavage. Mice were then euthanized by isoflurane inhalation and cervical dislocation. Whole livers were resected and the gall bladder removed, then rinsed in 1x PBS. Livers were diced into fine pieces and cross linked in 1% formaldehyde for 10 minutes at RT. Cross-linking was stopped by addition of 500 mM glycine. Tissue was pelleted via centrifugation at 3,200xg for 5 minutes at 4°C. Pellet was resuspended in 6 mL cold 1x PBS and homogenized using a dounce homogenizer with a tight pestle (Wheaton, Millville, New Jersey). The homogenate was pelleted at 3,200xg for 5 minutes at 4°C and resuspended in 5mL cell lysis buffer (150 mM NaCl, 25 mM Tris pH 7.5, 5 mM EDTA, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate) supplemented with protease inhibitor cocktail (Sigma p8340), and homogenized in a dounce homogizer with a tight pestle. Homogenates were incubated on ice for 15 minutes and centrifuged at 3,200xg for 5 minutes at 4°C. The samples were processed for ChIP using the Active Motif ChIP-IT Express Enzymatic Kit (Active Motif, Carlsbad, CA). Protein DNA complexes were immunoprecipitated with the following antibodies:

mouse monoclonal anti-AhR (ab2769 Abcam, Cambridge MA), goat polyclonal anti-KLF6 (SC-20885 Santa Cruz Biotechnology), mouse monoclonal anti-histone H3 (ab10799 Abcam, Cambridge MA), or rabbit monoclonal IgG Isotype control (#3900, Cell Signaling Technologies, Danvers, MA). Immunoprecipitated DNA was purified by phenol-chloroform extraction and ethanol precipitation. Cyp1a1 and p21^{Cip1} promoter sequences were amplified by PCR using primers flanking the XRE and NC-XRE sequences, respectively (Table 1). PCR products were resolved on a 5% polyacrylamide TBE gel and stained with 1x SYBR green for 30 minutes in the dark. Gels were rinsed with dH₂O and imaged on a Typhoon Trio Variable Mode Imager (GE Healthcare Life Sciences). Band intensity was measured using ImageQuant software (GE Healthcare Life Sciences).

Statistical Analysis. Data were analyzed using Prism 6 software. Animal numbers for surgery experiments were based on a preliminary power analysis. Statistical significance of $p < 0.05$ was used for all experiments. Unless otherwise indicated, significance was determined by Holm-Sidak t-test.

Results

We have previously shown that persistent AhR activation by TCDD suppresses liver regeneration in wild-type (WT) mice following 70% PH, concomitant with a decrease in CDK2 activity (Mitchell et al., 2006). In order to test the hypothesis that this anti-proliferative response was due to the p21^{Cip1} and/or p27^{Kip1} CDK inhibitors, we monitored hepatocyte proliferation in regenerating livers in WT, p21^{Cip1} and p27^{Kip1} knockout mice following TCDD treatment (Fig. 1). Commitment to DNA synthesis (S phase) was measured using 5-bromo-2'-deoxyuridine (BrdU) incorporation at various times after the PH. Substantial BrdU incorporation was first detected in WT mice at 36 hours post PH in keeping with a precisely regulated temporal program (Weglarz and Sandgren, 2000). Consistent with our previous findings (Mitchell et al., 2006), a significant decrease in BrdU positive nuclei is detected in livers from TCDD pretreated WT mice. Extensive BrdU incorporation occurred 12 hours sooner in the hepatectomized p21^{Cip1} KO mice, and significantly, the anti-proliferative property associated with TCDD treatment was absent in the p21^{Cip1} null background, suggesting that p21^{Cip1} plays a critical role in regulating normal liver regeneration. In contrast, BrdU incorporation in p27^{Kip1} KO mice was modest in both vehicle and TCDD-treated WT mice although peak DNA synthesis matched the temporal process observed in WT mice. TCDD-induced inhibition of DNA synthesis was reproducibly detected in the p27^{Kip1} KO mouse livers, but only 72 h post surgery. These findings suggest that p21^{Cip1} rather than p27^{Kip1} plays a critical role in regulating passage through G₁-phase during liver regeneration, and that loss of p21^{Cip1} function both hastens entry into S-phase and abrogates the AhR-mediated TCDD induced growth arrest. Indeed, Albrecht

and coworkers have previously demonstrated that loss of p21^{Cip1} accelerated hepatocyte progression through the G₁-phase after PH (Albrecht et al., 1998). BrdU incorporation was minimal (<4%) in sham-operated mice that were pretreated with either vehicle or TCDD (data not shown).

To examine the cumulative effect of p21^{Cip1} or p27^{Kip1} loss on liver regeneration, we performed a continuous BrdU labeling study over a 120 hour period following partial liver resection in WT, p21^{Cip1} KO, and p27^{Kip1} KO mice (Fig. 2). The immunohistochemical data show that over the course of 5 days, DNA synthesis occurred in 85-100% of the hepatic nuclei in vehicle-treated mice irrespective of the genotype. In contrast, TCDD pretreatment suppressed liver cell proliferation in the WT and p27^{Kip1} KO mice by about 50-60%, while the p21^{Cip1} KO mouse livers were completely resistant to the TCDD effect. These data support the BrdU pulse labeling results (Fig. 1). We also observed hydropic degeneration in the hepatectomized livers from TCDD treated WT and p27^{Kip1} KO mice that was undetectable in the p21^{Cip1} KO mouse livers. The precise molecular basis for this difference is unknown, but is suggestive of a link between p21^{Cip1} activity and the TCDD induced pathology detected in the liver sections.

Given the finding that p21^{Cip1} KO mouse livers entered S-phase prematurely and were refractory to the TCDD effects, we examined CDK2 expression and function in these livers. CDK2 protein levels transiently increased during the first 24 h post PH, but remained largely unaltered during the subsequent 48 h of liver regeneration and

showed no TCDD dependency (Fig. 3A). Consistent with observations made in WT mice (Albrecht et al., 1998), co-immunoprecipitation of the p27^{Kip1} protein in the p21^{Cip1} null background revealed that CDK2 binding increased marginally following PH. Moreover, formation of the p27^{Kip1}/CDK2 complex did not display a TCDD dependency. Assessment of CDK2 activity in p21^{Cip1} KO mice readily detected enhanced kinase activity by 24 h post-PH (Fig. 3B), without the pronounced TCDD induced inhibition seen in WT mice (Mitchell et al., 2006). Whereas CDK2 activity is first evident at 36 h post PH in WT mice (Albrecht et al., 1998),(Mitchell et al., 2006), detecting CDK2 activity by 24 h in the p21^{Cip1} KO mice underscores the accelerated commitment to DNA synthesis. Therefore, despite the presence of p27^{Kip1}, the lack of p21^{Cip1} resulted in premature up-regulation of CDK2 activity, and loss of TCDD induced growth arrest. Under normal physiological conditions, p21^{Cip1} expression is largely undetectable in the quiescent liver, although PH triggers p21^{Cip1} gene expression (Albrecht et al., 1998). In contrast, p21^{Cip1} expression is inducible in quiescent mouse livers following TCDD treatment for 24 hours (Fig. 4A). In fact, significant hepatic p21^{Cip1} mRNA induction was evident within 2 hours of TCDD treatment in WT mice but not in the hepatocyte specific AhR conditional KO (CKO) mice lacking receptor protein expression in the liver parenchyma (Fig. 4B), suggesting that p21^{Cip1} is indeed an AhR target gene. A comparable observation was made for the prototypical AhR target gene, Cyp1a1, exhibiting robust induction in WT livers that was markedly attenuated in the CKO mouse liver (Fig. 4C). The residual ($\approx 2\%$) Cyp1a1 induction observed is attributed to AhR activity in the non-parenchymal cells (e.g. stellate cells, endothelial cells, and Kupffer cells) that retained AhR expression in this CKO model. In contrast, p27^{Kip1} mRNA levels

did not change following TCDD exposure indicating that this is not a TCDD responsive murine gene *in vivo*, despite being TCDD responsive in the 5L rat hepatoma cell line (Kolluri et al., 1999).

In order to verify that p21^{Cip1} is an AhR target gene, we performed chromatin immunoprecipitation (ChIP) assays. However, prior to assaying for AhR binding to the p21^{Cip1} promoter *in vivo*, it was first necessary to ascertain which of two alternate promoters (Gartel et al., 2004) conferred TCDD inducible p21^{Cip1} expression in the liver. A third alternate p21^{Cip1} transcript has been described previously (Huppi et al., 1994), but is not expressed in the liver (Gartel et al., 2004). The genomic context for the two transcripts expressed in the liver are shown in Figure 5A. Transcription is under the control of two distinct promoters, where transcripts 1 and 2 differ in their 5' untranslated region, but encode the same p21^{Cip1} protein. RT-PCR on total RNA using variant-specific primers revealed that the downstream promoter is by far the dominant promoter during liver regeneration as well as in response to TCDD treatment (Fig. 5B). Our lab recently documented that the NC-XRE is a functional target site for a novel interaction involving the tumor suppressor KLF6 and the AhR (Wilson et al., 2013). It is noteworthy that the downstream promoter of p21^{Cip1} contains a NC-XRE. Given the previous finding that p21^{Cip1} is a KLF6 target gene (Narla et al., 2001; 2007), ChIP assays concentrated on the NC-XRE containing promoter region. ChIP experiments were performed on mouse liver tissue obtained from animals treated with vehicle or TCDD via oral gavage. PCR amplification of the genomic region encompassing the NC-XRE revealed that both the AhR and KLF6 proteins were recruited to the promoter within 2 h

following TCDD exposure (Fig. 6A). Analysis on quantitated replicate experiments confirmed that AhR and KLF6 DNA binding is significantly increased by TCDD treatment, consistent with the rapid increase in p21^{Cip1} mRNA (Fig. 4B). DNA binding by the AhR-KLF6 complex to the p21^{Cip1} promoter persists for at least 24 hours following TCDD exposure (Fig. 6B, sham surgery). Significantly, PH—in the absence of TCDD—also induced recruitment of the AhR and KLF6 to the p21^{Cip1} promoter within 2 h (Fig. 6B, partial hepatectomy), consistent with the transient increase of transcript 2 following PH (Fig. 5B). TCDD pretreatment potentiated AhR-KLF6 binding to the p21^{Cip1} promoter in hepatectomized livers in keeping with the enhanced mRNA expression.

These data indicate that PH triggers AhR activation in the absence of an exogenous agonist such as TCDD. The evidence for spontaneous AhR activation following PH resulting in p21^{Cip1} expression (Fig. 6) is further supported by an increase in P4501A1 protein expression observed during the first 48 hours following PH (Fig. 7). This represents a transient induction of the Cyp1a1 gene attributed to an endogenous signaling mechanism activating the AhR that was previously observed during liver regeneration (Mitchell et al., 2006). The surprising observation that this Cyp1a1 induction is attenuated in the p21^{Cip1} KO mice following PH implies that AhR functionality is dependent on a p21^{Cip1}-regulated process absent in the null mice.

Discussion

Current understanding of the signaling events that regulate liver regeneration after two-thirds PH is incomplete. While 70% PH induces most of the remaining hepatocytes to replicate at least once before exiting the cell cycle, we have shown that TCDD treatment can disrupt the normal regenerative process following PH, with fully half of the hepatocytes in the liver remnant failing to proliferate (Mitchell et al., 2006). The study also demonstrated that CDK2 activity, rather than CDK4 activity, was inhibited by TCDD treatment. Hence, the work reported here focused on the CDK2 inhibitors, p21^{Cip1} and p27^{Kip1}, rather than the INK4 inhibitors known to suppress CDK4 activity (Sherr and Roberts, 1995). Moreover, TCDD induced growth arrest in the 5L rat hepatoma cell line was attributed to p27^{Kip1} function (Kolluri et al., 1999; Levine-Fridman et al., 2004). However, the present finding using KO mice demonstrated that *in vivo*, p21^{Cip1} rather than p27^{Kip1} conferred the TCDD induced inhibition in liver regeneration. BrdU incorporation studies revealed that loss of p27^{Kip1} did not substantially alter the TCDD induced inhibition in hepatocyte proliferation observed in wild-type mice (Fig. 2). In contrast, the absence of p21^{Cip1} expression completely abrogated the TCDD effect seen in WT mice. Accordingly, CDK2 activity in the p21^{Cip1} KO mouse liver was unaffected by TCDD treatment (Fig. 3B), juxtaposing the earlier findings in WT mice where TCDD treatment inhibited CDK2 activity (Mitchell et al., 2006). In keeping with other studies (Albrecht et al., 1998), PH increased CDK2 activity in p21^{Cip1} KO mice at 24 hours, substantially earlier than the peak of CDK2 activity normally observed at 36 hours post PH (Mitchell et al., 2006). This is congruent with the accelerated commitment to S-phase measured by BrdU incorporation (Fig. 1). Collectively, the results indicate that

TCDD induced growth arrest in the regenerating liver is absolutely dependent on p21^{Cip1} activity, and that p27^{Kip1} does not confer functional redundancy. The finding that p21^{Cip1} rather than p27^{Kip1} is required for the TCDD effect *in vivo*, also bolsters the recognition that studies examining cell cycle control in tissue culture systems cannot automatically be extrapolated to liver regeneration *in vivo* (Kren and Steer, 1996; Loyer et al., 1994).

p21^{Cip1} is the founding member of the Cip/Kip family of cyclin-dependent kinase inhibitors (Gartel et al., 1996). Expression of p21^{Cip1} is controlled mostly at the transcriptional level by both p53-dependent and p53-independent mechanisms (Gartel and Tyner, 1999). Although the p21^{Cip1} genomic locus is organized differently in mice and humans, both produce multiple transcripts utilizing different promoters (Nozell and Chen, 2002; Gartel et al., 2004). In mice, expression of the classical transcript (transcript 2) is p53-independent (Gartel et al., 2004). This transcript appears to be the dominant transcript up-regulated following PH and exposure to TCDD (Fig. 5B). It is noteworthy that the promoter regulating transcript 2 contains a NC-XRE. We recently showed that the NC-XRE is an AhR DNA-binding site. AhR mediated regulation of gene expression via the NC-XRE occurs through a mechanism involving the novel binding partner, KLF6 (Huang and Elferink, 2012; Wilson et al., 2013). The basis for the modest increase in transcript 1 detected after PH and TCDD treatment is uncertain (Fig. 5B). As such, further studies are required to explore whether this increased expression is due to direct transcriptional regulation of the upstream promoter or a secondary consequence of transcriptional activation at the downstream promoter. Albrecht and coworkers demonstrated that in contrast to p27^{Kip1} expression, which changed little during liver

regeneration, p21^{Cip1} expression, although undetectable in the quiescent liver, was dramatically induced within 3 hours following PH (Albrecht et al., 1997) (Albrecht et al., 1998). Our data show that p21^{Cip1} transcript levels transiently peaked at 48 hour post PH declining thereafter. Induction of p21^{Cip1} by TCDD is detectable at the mRNA level within 2 hours (Fig. 4B), rapidly reaching a sustained level exceeding the increase observed following PH alone (Fig. 5B). The lack of induction in the AhR CKO mouse liver suggests that p21^{Cip1} is an AhR target gene. Accordingly, p21^{Cip1} induction is concomitant with recruitment of the AhR and KLF6 to the transcript 2 promoter region harboring the NC-XRE (Fig. 6). KLF6 was first implicated in regulating p53-independent p21^{Cip1} expression in human prostate cancer (Narla et al., 2001). More recently, studies in transgenic mice over-expressing KLF6 in the liver showed marked p21^{Cip1} expression and diminished hepatocyte proliferation (Narla et al., 2007). These authors concluded that KLF6 was a critical regulator of hepatocyte proliferation and liver size *in vivo*, through a mechanism dependent in large part on p21^{Cip1} expression. Remarkably, the phenotype in the transgenic KLF6 mice closely resembled that observed in p21^{Cip1} transgenic mice over-expressing the kinase inhibitor in hepatocytes (Wu et al., 1996). Moreover, liver regeneration in the p21^{Cip1} transgenic mice was markedly attenuated following PH (0.5%-14.5% of normal). Collectively, these data suggest that the increase in p21^{Cip1} expression during hepatocyte proliferation following PH contributes to the normal temporal process associated with liver regeneration; prolonged and elevated p21^{Cip1} expression in the transgenic mice, however impedes hepatocyte proliferation. We conclude that TCDD treated, hepatectomized mice similarly show enhanced

induction of p21^{Cip1} expression through an AhR-KLF6 dependent transcriptional response resulting in growth arrest.

Hyperphosphorylation and concomitant inactivation of the Rb protein is considered to be the major function of the G₁ and S phase CDKs (Sherr and Roberts, 2004). Rb protein inactivation triggers its release from E2F, allowing for the transcriptional activation of S phase genes, thus resulting in cell cycle progression. Therefore, circumstances that interfere with CDK activation inhibit cell proliferation. Albrecht and coworkers (Albrecht et al., 1998) showed that Rb protein hyperphosphorylation and loss of E2F binding occurred sooner (36 hours versus 48 hours) in partially hepatectomized p21^{Cip1} KO mice as compared to wild-type mice, consistent with the shortened G₁ interval. Given our previous observation that the active (hypophosphorylated) Rb protein also binds to the AhR and contributes to AhR transcriptional activity (Ge and Elferink, 1998; Elferink et al., 2001; Levine-Fridman et al., 2004), it is reasonable to speculate that processes, which facilitate Rb protein inactivation may also disrupt AhR activity. This prediction is borne out by the failure of PH to increase P4501A1 expression in the p21^{Cip1} KO mouse liver, a response normally observed in the regenerating liver of wild-type mice (Fig. 7). Based on the data we have collected and the findings presented elsewhere, we propose the following model (Fig. 8). Liver regeneration following PH results in AhR activation as evidenced by AhR recruitment to the p21^{Cip1} promoter and P4501A1 induction, which involves AhR binding to the NC-XRE and XRE, respectively. Receptor binding to the XRE is in concert with the Arnt protein while NC-XRE binding depends on partnering with KLF6. Under normal physiological conditions p21^{Cip1} expression is increased to

temporally regulate G₁ phase CDK activity and Rb protein inactivation. The absence of p21^{Cip1} hastens passage through G₁ phase of the cell cycle by inactivating the Rb protein prematurely. Conversely, prolonged over-expression of p21^{Cip1} due to TCDD treatment inhibits G₁ phase kinase activity and delays Rb protein inactivation. Under normal physiological conditions the consequent increase in P4501A1 activity is presumed to facilitate the metabolic clearance of endogenous AhR agonists (Chang and Puga, 1998) resulting in attenuated AhR transcriptional activity, thus restoring balance to the signaling processes. However, because TCDD is refractory to metabolic clearance of the aforementioned endogenous agonists by P4501A1, AhR activity persists, thereby resulting in prolonged p21^{Cip1} expression and cell cycle arrest. Conversely, since the Rb protein functions as an AhR co-activator in Cyp1a1 gene expression (Ge and Elferink, 1998; Elferink et al., 2001; Levine-Fridman et al., 2004), the absence of p21^{Cip1} is expected to hasten Rb protein inactivation to promote cell cycle progression and thus impair Cyp1a1 induction.

In conclusion, we have shown that TCDD induced suppression of liver regeneration depends on induction of the p21^{Cip1} gene involving recruitment of the AhR-KLF6 complex to the NC-XRE present in the downstream promoter. Moreover, p21^{Cip1} rather than p27^{Kip1} confers the AhR-mediated attenuation of liver regeneration, and absence of p21^{Cip1} abrogates the TCDD induced effect on liver regeneration. The data also attest to integrated signaling of multiple AhR target genes regulated by distinct DNA recognition sites.

Acknowledgments

The authors wish to thank Dr. Tod Harper for assistance with the p21 transcript experiments. We also wish to thank the UTMB Histopathology Core for preparing and staining liver tissue and Deborah Prusak of the UTMB Molecular Genomics core for running the qRT-PCR experiments.

Authorship contributions

Participated in research design: Jackson, Li, Mitchell, Elferink

Conducted experiments: Jackson, Li, Mitchell, Joshi,

Performed data analysis: Jackson, Li, Mitchell, Joshi, Elferink

Wrote or contributed to the writing of the manuscript: Jackson, Elferink

References

- Abdelrahim, M., Smith, R., and Safe, S. (2003). Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells. *Molecular Pharmacology* 63, 1373–1381.
- Albrecht, J.H., Meyer, A.H., and Hu, M.Y. (1997). Regulation of cyclin-dependent kinase inhibitor p21WAF1/Cip1/Sdi1 gene expression in hepatic regeneration. *Hepatology* 25, 557–563.
- Albrecht, J.H., Poon, R.Y., Ahonen, C.L., Rieland, B.M., Deng, C., and Crary, G.S. (1998). Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. *Oncogene* 16, 2141–2150.
- Chang, C.Y., and Puga, A. (1998). Constitutive activation of the aromatic hydrocarbon receptor. *Molecular and Cellular Biology* 18, 525–535.
- Denison, M.S., and Nagy, S.R. (2003). Activation of The Aryl Hydrocarbon Receptor by Structurally Diverse Exogenous and Endogenous Compounds. *Annual Review of Pharmacology and Toxicology*. 43, 309–334.
- Denison, M.S., Soshilov, A.A., He, G., DeGroot, D.E., and Zhao, B. (2011). Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. *Toxicological Sciences* 124, 1–22.
- Elferink, C.J., Ge, N.L., and Levine, A. (2001). Maximal aryl hydrocarbon receptor activity depends on an interaction with the retinoblastoma protein. *Molecular Pharmacology* 59, 664–673.

Fernandez-Salguero, P.M., Hilbert, D.M., Rudikoff, S., Ward, J.M., and Gonzalez, F.J. (1996). Aryl-hydrocarbon Receptor-Deficient Mice Are Resistant to 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Induced Toxicity. *Toxicology and Applied Pharmacology* 140, 173-179

Fukunaga, B.N., Probst, M.R., Reisz-Porszasz, S., and Hankinson, O. (1995). Identification of functional domains of the aryl hydrocarbon receptor. *Journal of Biological Chemistry* 270, 29270–29278.

Gartel, A.L., Serfas, M.S., Gartel, M., Goufman, E., Wu, G.S., el-Deiry, W.S., and Tyner, A.L. (1996). p21 (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. *Experimental Cell Research* 227, 171–181.

Gartel, A.L., and Tyner, A.L. (1999). Transcriptional Regulation of the p21(WAF1/CIP1) Gene. *Experimental Cell Research* 246, 280–289.

Gartel, A.L., Radhakrishnan, S.K., Serfas, M.S., Kwon, Y.H., and Tyner, A.L. (2004). A novel p21WAF1/CIP1 transcript is highly dependent on p53 for its basal expression in mouse tissues. *Oncogene* 23, 8154–8157.

Ge, N.-L., and Elferink, C.J. (1998). A Direct Interaction between the Aryl Hydrocarbon Receptor and Retinoblastoma Protein. *Journal of Biological Chemistry* 273, 22708-22713

Gottlicher, M., and Wiebel, F.J. (1991). 2,3,7,8-Tetrachlorodibenzo-p-dioxin causes unbalanced growth in 5L rat hepatoma cells. *Toxicology and Applied Pharmacology* 111, 496–503.

Hankinson, O. (1995). The Aryl Hydrocarbon Receptor Complex. *Annual Review of Pharmacology and Toxicology* 35, 307–340.

Huang, G., and Elferink, C.J. (2012). A Novel Nonconsensus Xenobiotic Response Element Capable of Mediating Aryl Hydrocarbon Receptor-Dependent Gene Expression. *Molecular Pharmacology* 81, 338–347.

Huang, G., and Elferink, C.J. (2005). Multiple Mechanisms Are Involved in Ah Receptor-Mediated Cell Cycle Arrest. *Molecular Pharmacology* 67, 88–96.

Huppi, K., Siwarski, D., Dosik, J., Michieli, P., Chedid, M., Reed, S., Mock, B., Givol, D., and Mushinski, J.F. (1994). Molecular cloning, sequencing, chromosomal localization and expression of mouse p21 (Waf1). *Oncogene* 9, 3017–3020.

Kolluri, S., Weiss, C., Koff, A., and Gottlicher, M. (1999). p27Kip1 induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. *Genes & Development* 13, 1742–1753.

Kren, B.T., and Steer, C.J. (1996). Post-transcriptional regulation of gene expression in liver regeneration: role of mRNA stability. *The FASEB Journal* 10, 559–573.

Levine-Fridman, A., Chen, L., and Elferink, C.J. (2004). Cytochrome P4501A1 promotes G1 phase cell cycle progression by controlling aryl hydrocarbon receptor activity.

Molecular Pharmacology 65, 461–469.

Loyer, P., Glaise, D., Cariou, S., Baffet, G., Meijer, L., and Guguen-Guillouzo, C. (1994). Expression and activation of cdk2 (1 and 2) and cyclins in the cell cycle progression during liver regeneration. *Journal of Biological Chemistry* 269, 2491–2500.

Ma, Q., and Whitlock, J.P. (1996). The aromatic hydrocarbon receptor modulates the Hepa 1c1c7 cell cycle and differentiated state independently of dioxin. *Molecular and Cellular Biology* 16, 2144–2150.

Marlowe, J.L., Knudsen, E.S., Schwemberger, S., and Puga, A. (2004). The aryl hydrocarbon receptor displaces p300 from E2F-dependent promoters and represses S phase-specific gene expression. *Journal of Biological Chemistry* 279, 29013–29022.

Mitchell, K.A., Lockhart, C.A., Huang, G., and Elferink, C.J. (2006). Sustained Ah receptor activity attenuates liver regeneration. *Molecular Pharmacology* 70, 163–170.

Mitchell, K.A., Wilson, S.R., and Elferink, C.J. (2010). The activated aryl hydrocarbon receptor synergizes mitogen-induced murine liver hyperplasia. *Toxicology* 276, 103–109.

Narla, G., Heath, K., Reeves, H.L., Li, D., Giono, L., Kimmelman, A., Glucksman, M., Narla, J., Eng, F., Chan, A.M., et al. (2001). KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer. *Science* 294, 2563–2566.

Narla, G., Kremer-Tal, S., Matsumoto, N., Zhao, X., Yao, S., Kelley, K., Tarocchi, M., and Friedman, S.L. (2007). In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma. *Oncogene* 26, 4428–4434.

Nebert, D.W., Puga, A., and Vasiliou, V. (1993). Role of the Ah receptor and the dioxin-inducible [Ah] gene battery in toxicity, cancer, and signal transduction. *Ann. N. Y. Acad. Sci.* 685, 624–640.

Nozell, S., and Chen, X. (2002). p21B, a variant of p21Waf1/Cip1, is induced by the p53 family. *Oncogene* 21, 1285–1294.

Poland, A., and Knutson, J.C. (1982). 2, 3, 7, 8-tetrachlorodibenzo-thorn-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. *Annual Review of Pharmacology and Toxicology* 22, 517-554

Probst, M.R., Reisz-Porszasz, S., Agbunag, R.V., Ong, M.S., and Hankinson, O. (1993). Role of the aryl hydrocarbon receptor nuclear translocator protein in aryl hydrocarbon (dioxin) receptor action. *Molecular Pharmacology* 44, 511–518.

Puga, A., Barnes, S.J., Dalton, T.P., Chang, C.Y., Knudsen, E.S., and Maier, M.A. (2000). Aromatic hydrocarbon receptor interaction with the retinoblastoma protein potentiates repression of E2F-dependent transcription and cell cycle arrest. *Journal of Biological Chemistry* 275, 2943–2950.

- Reisz-Porszasz, S., Probst, M.R., Fukunaga, B.N., and Hankinson, O. (1994). Identification of functional domains of the aryl hydrocarbon receptor nuclear translocator protein (ARNT). *Molecular and Cellular Biology* 14, 6075–6086.
- Safe, S.H. (1986). Comparative toxicology and mechanism of action of polychlorinated dibenzo-p-dioxins and dibenzofurans. *Annual Review of Pharmacology and Toxicology*
- Sherr, C.J., and Roberts, J.M. (1995). Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes & Development* 9, 1149–1163.
- Sherr, C.J., and Roberts, J.M. (2004). Living with or without cyclins and cyclin-dependent kinases. *Genes & Development*. 18, 2699-2711
- Swanson, H.I., Chan, W.K., and Bradfield, C.A. (1995). DNA binding specificities and pairing rules of the Ah receptor, ARNT, and SIM proteins. *Journal of Biological Chemistry* 270, 26292–26302.
- Watson, A.J., and Hankinson, O. (1992). Dioxin- and Ah receptor-dependent protein binding to xenobiotic responsive elements and G-rich DNA studied by in vivo footprinting. *Journal of Biological Chemistry* 266, 6874-6878
- Weglarz, T.C., and Sandgren, E.P. (2000). Timing of hepatocyte entry into DNA synthesis after partial hepatectomy is cell autonomous. *Proceedings of the National Academy of Sciences* 97, 12595–12600.

Weiss, C., Kolluri, S.K., Kiefer, F., and Gottlicher, M. (1996). Complementation of Ah receptor deficiency in hepatoma cells: negative feedback regulation and cell cycle control by the Ah receptor. *Experimental Cell Research* 226, 154–163.

Whitlock, J.P. (1999). Induction of cytochrome P4501A1. *Annual Review of Pharmacology and Toxicology* 39, 103–125.

Wilson, S.R., Joshi, A.D., and Elferink, C.J. (2013). The Tumor Suppressor Kruppel-Like Factor 6 is a Novel Aryl Hydrocarbon Receptor DNA Binding Partner. *Journal of Pharmacology and Experimental Therapeutics* 345, 419-429

Wu, H., Wade, M., Krall, L., Grisham, J., Xiong, Y., and Van Dyke, T. (1996). Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. *Genes & Development* 10, 245–260.

Footnotes

This work was supported by the National Institute of Health National Institute of Environmental Health Sciences grant [R01ES07800], [P30ES006676] and [T32ES007254].

Legends for Figures

Figure 1. Analysis of hepatocyte proliferation during liver regeneration in vehicle or TCDD-treated wild-type, p27^{Kip1} KO mice, or p21^{Cip1} KO mice. Mice were treated for 24 hours with vehicle or TCDD prior to PH (t=0 hours). Animals were pulsed with BrdU 2 hours before euthanization at indicated time points. BrdU-positive cells are identified by the dark brown (3,3-diaminobenzidine-stained) nuclei in the photomicrographs (200). Nuclei were counted in six random fields (>300 cells/field) in liver tissue from each mouse. Data represent the average percent positive nuclei from 3 animals per treatment group for each genotype, and are representative of 3 separate experiments. Data are plotted as mean \pm S.E.M. An asterisk indicates a significant difference between the vehicle and TCDD treated groups ($p < 0.05$).

Figure 2. TCDD induced suppression of liver regeneration is specifically abrogated in p21^{Cip1} KO mice. **A**, Representative sections of cumulative BrdU incorporation during liver regeneration in wild-type, p21^{Cip1} KO, or p27^{Kip1} KO mice. Mice were treated for 24 hours with vehicle or TCDD prior to PH surgery, and provided BrdU in the drinking water (0.8 mg BrdU/ml, shielded from light) for a period of 5 days post PH. Liver tissue was processed and stained for immunohistochemistry, and BrdU-positive cells identified by as dark brown (3,3-diaminobenzidine-stained) nuclei in the photomicrographs. **B**, Cumulative BrdU incorporation was quantified as described in Fig. 1. Data represent the average percent positive nuclei from 3 animals per treatment group and are representative of 3 separate experiments. Data are plotted as mean \pm S.E.M. An asterisk indicates significant difference between the vehicle and TCDD

treated groups ($p < 0.05$).

Figure 3. CDK2 expression and activity in the p21^{Cip1} KO mice. **A**, p21^{Cip1} KO mice were treated with vehicle or TCDD for 24 hours prior to PH, and euthanized at the indicated times post surgery. Livers were harvested and homogenized followed by immunoprecipitation with anti-CDK2 antibody. Immunoprecipitates were fractionated by SDS-PAGE and probed sequentially for CDK2 and p27^{Kip1} by western blotting. Blots are representative of at least three separate experiments, and a non-specific (NS) band routinely detected on the CDK2 blots was used as a loading control. **B**, CDK2 kinase assays were performed on liver homogenates from mice treated as in **(A)**. Homogenates were immunoprecipitated with an anti-CDK2 antibody and Protein-A/G beads. Bead bound CDK2 was incubated with histone H1 and 32P- γ ATP and radiolabeled histone H1 visualized by autoradiography.

Figure 4. AhR dependent expression of p21^{Cip1} expression in the murine liver. **A**, Wild-type mice were treated with vehicle or TCDD by gavage 24 hours prior to euthanization and total RNA prepared from the liver. qRT-PCR was performed on the RNA for to measure the p21^{Cip1} mRNA level. Data represent the average value for RNA isolated from five independent experiments for each treatment. Data are plotted as mean \pm S.E.M. Asterisk indicates a significant difference between vehicle and TCDD treated animals ($p < 0.01$). **B**, Wild-type and AhR CKO mice were treated with vehicle or TCDD by gavage 2 hours prior to sacrifice. p21^{Cip1} mRNA levels were measured by qRT-PCR on total RNA. Data are representative of six wild-type animals per treatment

and four AhR CKO animals per treatment. Data are plotted as mean \pm S.E.M. An asterisk indicates a significant difference between the vehicle and TCDD treated animals ($p < 0.05$). **C**, qRT-PCR on total RNA isolated in B, was performed to measure CYP1A1 and p27^{Kip1} expression.

Figure 5. Differential expression of the p21^{Cip1} locus in the mouse genome. A, Diagrammatic representation of the p21^{Cip1} locus encoding liver expressed transcripts. The diagram also identifies the location of the NC-XRE and the variant-specific primers used for RT-PCR and ChIP analysis. **B**, Mice were treated with vehicle or TCDD for 24 hours prior to PH surgery, and euthanized at the indicated times after surgery. Primers specific for transcripts 1, transcript 2 and GAPDH were used in RT-PCR and the products visualized by agarose gel electrophoresis. Data are representative of three separate experiments.

Figure 6. ChIP analysis on the p21^{Cip1} transcript 2 promoter encompassing the NC-XRE. A, Mice were treated with vehicle or TCDD via gavage for 2 hours. Livers were excised and processed for ChIP on the AhR and KLF6. IgG and histone H3 antibodies were used as negative and positive controls, respectively. PCR products were fractionated by 6% PAGE and stained with SYBR Green, and quantitation was presented as a percentage of the input DNA. The data shown are representative of four independent experiments. Data are plotted as mean \pm S.E.M. An asterisk indicates a significant difference between vehicle and TCDD treatments via one-sided ratio-paired t-tests. ($p < 0.05$). **B**, Mice were treated with vehicle or TCDD by gavage for 24 hours


prior to sham surgery (top) or PH (bottom). Mice were euthanized 2 hours after surgery, and livers were processed for ChIP. Gels are representative of three separate experiments.



Figure 7. AhR activation is disrupted in p21^{Cip1} KO mice. Wild-type and p21^{Cip1} KO mice were subjected PH and euthanized at the indicated times. Livers were excised and processed for western blot analysis to detect P4501A1 protein levels. Blot is representative of three experiments.



Figure 8. AhR signal integration during liver regeneration. Activation of the AhR in response to an exogenous agonist or endogenous cue stimulates nuclear translocation and chaperone dissociation. The liganded AhR partners with either the Arnt protein or KLF6 followed by binding to the XRE and NC-XRE, respectively. Under normal physiological conditions the AhR-Arnt heterodimer induces Cyp1a1 expression and subsequent metabolic turnover of the AhR agonist to prevent sustained AhR activation. Concomitantly the AhR-KLF6 heterodimer induces p21^{Cip1} expression to modulate CDK2 activity and affect the rate of Rb protein inactivation. Since the hypophosphorylated (active) Rb protein contributes to AhR-Arnt dependent Cyp1a1 expression, the level of p21^{Cip1} expression indirectly affects Cyp1a1 expression. This cross-talk imputes G₁ phase cell cycle progression with a delicate mechanism to fine tune AhR activity and subsequent p21^{Cip1} expression.


Table 1- PCR Primers

Gene	Forward	Reverse
p21^{Cip1} qRT-PCR	TGTCTTGCACTCTGGTGTCTGAG	CAATCTGCGCTTGGAGTGATAG
p27^{Kip1} qRT-PCR	TCCAGGGATGAGGAAGCG	CTCCACAGTGCCAGCGTTC
p21^{Cip1} Transcript 1	GGAGCATGAATGGAGACAGAGACC	ACCAGAGTGCAAGACAGCGACAAG
p21^{Cip1} Transcript 2	AGCAGCCGAGAGGTGAGC	ACCAGAGTGCAAGACAGCGACAAG
GAPDH	ACGGCAAATTC AACGGCACAGTCA	CATTGGGGGTAGGAACACGGAA
p21^{Cip1} ChIP	GTTAGTCCTTCCCACAGTTGGT	CGTCGAGCTGCCTCCTTAT
CYP1A1 qRT-PCR	GCCTAACTCTTCCCTGGATGC	TCAATGAGGCTGTCTGTGATGTC







A**B**




A



B



A



B




Figure 7




Figure 8

